Review



anti csfr1 antibody treatment  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 98
      Buy from Supplier

    Structured Review

    Bio X Cell anti csfr1 antibody treatment
    Anti Csfr1 Antibody Treatment, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 817 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+csfr1+antibody+treatment/Anti-Dopamine+Receptor+D3+Rabbit+Monoclonal+Antibody/10__1158_slash_2326___6066__cir___19___0904-49-8-14
    Average 98 stars, based on 817 article reviews
    anti csfr1 antibody treatment - by Bioz Stars, 2026-09
    98/100 stars

    Images

    Related Articles

    In Vivo:

    Article Title: Hyperglycemia Enhances Cancer Immune Evasion by Inducing Alternative Macrophage Polarization through Increased O-GlcNAcylation
    Article Snippet: Depletion of intra-tumoral macrophages was achieved by i.p. anti-CSFR1 antibody treatment (CD115, clone AFS98, BioXCell) with a total of 7 injections, 1 mg before tumor inoculation, followed by 6 injections of 400 μg each every 3 to 4 days over 3 weeks.. HBP inhibition in vivo was achieved by treatment of tumor bearing mice with 3 doses (10 mg/kg) of DON (6-Diazo-5-oxo-L-norleucine, Sigma-Aldrich) every 3 days, beginning when tumors reached 300400 mm 3 .HBP inhibition in vivo was achieved by treatment of tumor bearing mice with 3 doses (10 mg/kg) of DON (6-Diazo-5-oxo-L-norleucine, Sigma-Aldrich) every 3 days, beginning when tumors reached 300400 mm 3 .

    Article Title: Hyperglycemia enhances cancer immune evasion by inducing alternative macrophage polarization through increased O-GlcNAcylation
    Article Snippet: Depletion of intra-tumoral macrophages was achieved by i.p. anti-CSFR1 antibody treatment (CD115, clone AFS98, BioXCell) with a total of 7 injections, 1 mg before tumor inoculation, followed by 6 injections of 400 µg each every 3 to 4 days over 3 weeks.. HBP inhibition in vivo was achieved by treatment of tumor bearing mice with 3 doses (10 mg/kg) of DON (6-Diazo-5-oxo-L-norleucine, Sigma-Aldrich) every 3 days, beginning when tumors reached 300–400 mm 3 .HBP inhibition in vivo was achieved by treatment of tumor bearing mice with 3 doses (10 mg/kg) of DON (6-Diazo-5-oxo-L-norleucine, Sigma-Aldrich) every 3 days, beginning when tumors reached 300–400 mm 3 .

    Injection:

    Article Title: Hyperglycemia Enhances Cancer Immune Evasion by Inducing Alternative Macrophage Polarization through Increased O-GlcNAcylation
    Article Snippet: Depletion of intra-tumoral macrophages was achieved by i.p. anti-CSFR1 antibody treatment (CD115, clone AFS98, BioXCell) with a total of 7 injections, 1 mg before tumor inoculation, followed by 6 injections of 400 μg each every 3 to 4 days over 3 weeks.. HBP inhibition in vivo was achieved by treatment of tumor bearing mice with 3 doses (10 mg/kg) of DON (6-Diazo-5-oxo-L-norleucine, Sigma-Aldrich) every 3 days, beginning when tumors reached 300400 mm 3 .HBP inhibition in vivo was achieved by treatment of tumor bearing mice with 3 doses (10 mg/kg) of DON (6-Diazo-5-oxo-L-norleucine, Sigma-Aldrich) every 3 days, beginning when tumors reached 300400 mm 3 .

    Article Title: Hyperglycemia enhances cancer immune evasion by inducing alternative macrophage polarization through increased O-GlcNAcylation
    Article Snippet: Depletion of intra-tumoral macrophages was achieved by i.p. anti-CSFR1 antibody treatment (CD115, clone AFS98, BioXCell) with a total of 7 injections, 1 mg before tumor inoculation, followed by 6 injections of 400 µg each every 3 to 4 days over 3 weeks.. HBP inhibition in vivo was achieved by treatment of tumor bearing mice with 3 doses (10 mg/kg) of DON (6-Diazo-5-oxo-L-norleucine, Sigma-Aldrich) every 3 days, beginning when tumors reached 300–400 mm 3 .HBP inhibition in vivo was achieved by treatment of tumor bearing mice with 3 doses (10 mg/kg) of DON (6-Diazo-5-oxo-L-norleucine, Sigma-Aldrich) every 3 days, beginning when tumors reached 300–400 mm 3 .



    Similar Products

    anti csfr1 antibody treatment  (Bio X Cell)
    98
    Bio X Cell anti csfr1 antibody treatment
    Anti Csfr1 Antibody Treatment, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+csfr1+antibody+treatment/Anti-Dopamine+Receptor+D3+Rabbit+Monoclonal+Antibody/10__1158_slash_2326___6066__cir___19___0904-49-8-14
    Average 98 stars, based on 1 article reviews
    anti csfr1 antibody treatment - by Bioz Stars, 2026-09
    98/100 stars
    		  Buy from Supplier

    Image Search Results